课题基金 / 基金详情

Chemical Library Screening

Chemical Library Screening
化学库筛选
批准号:
10686139
负责人:
Michael Jackson
金额:
$19.94万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-05-01 至 2025-04-30

项目摘要

项目成果

Michael Jackson的其他基金

相似基金

相关文献

中文摘要
翻译
抽象化学图书馆筛选共享资源 化学图书馆筛查(CLS)共享资源由癌症中心管理。此资源提供 中心科学家有能力开发和进行小型和大型化学图书馆筛查并执行 用于产生调节生化和细胞的选择性探针/导联的HIT优化和验证 癌症的过程。此外,CLS还为教师提供访问技术、专业知识和基础设施的途径 开发用于表征参与肿瘤启动和发病机制的细胞靶点的新分析方法的资源 以及推进用于抗肿瘤治疗的新先导分子的开发。CLS由四个专门的 但高度集成的设施:高通量分析开发(HT-AD)、复合管理和 高通量筛选(CM-HTS)、高含量筛选(HCS)以及药物化学和药物 代谢/药代动力学(MedChem/DMPK)。这些设施实际驻留在康拉德普雷比 位于SBP的化学基因组学中心(Prebys Center),占地12,000多平方米。英国《金融时报》实验室的 空间,拥有强大的HTS和HCS分析开发和筛查仪器能力。 CLS可以获得广泛的不同和专注的小分子收藏,几个集成的液体 处理系统和大量检测仪器,能够在任何模式下进行分析,包括 基于活细胞图像的分析需要温度和二氧化碳控制。Prebys中心由癌症发展而来 中心的CLS共享资源,这是在2003年CCSG续订中启动的。这一支持已被利用 有几个大的奖励金和慈善基金。最初被授予NIH分子十大奖项之一 图书馆筛选网络综合中心,Prebys中心后来被选为四个NIH- 指定分子文库探针生产中心网络综合筛选中心。它也是 NCI化学生物学联盟(CBC)的七个专门中心之一。尽管全球经济增长 Prebys中心,CLS核心对中心调查人员仍然至关重要,因为它提供了 重要的交互切入点,以确保它们从这些世界级技术中获得最大的科学利益 化学生物学和药物发现能力,使基础科学和转化科学 努力。在过去的5年中,该中心还启动了100个癌症检测开发项目 中心调查人员,导致>25个完整的HTS活动,以支持早期翻译的目标。它提供了 为代表所有三个项目的36名中心调查人员提供服务。生成的数据已支持24个 成功获得16个中心成员和众多出版物的资助,其中包括20本合著出版物 由CLS工作人员提供。
英文摘要
ABSTRACT – CHEMICAL LIBRARY SCREENING SHARED RESOURCE The Chemical Library Screening (CLS) Shared Resource is managed by the Cancer Center. This resource offers Center scientists the ability to develop and conduct small- and large-scale chemical library screens and perform hit optimization and validation for generating selective probes/leads modulating biochemical and cellular processes in cancer. In addition, CLS provides faculty with access to technology, expertise, and infrastructure resources to develop novel assays for characterizing cellular targets involved in tumor initiation and pathogenesis and to advance the development of new lead molecules for anti-tumor therapies. CLS consists of four specialized but highly integrated facilities: High-Throughput Assay Development (HT-AD), Compound Management and High-Throughput Screening (CM-HTS), High-Content Screening (HCS), and Medicinal Chemistry and Drug Metabolism/Pharmacokinetics (MedChem/DMPK). The facilities physically reside within the Conrad Prebys Center for Chemical Genomics (Prebys Center) at SBP, which occupies more than 12,000 sq. ft. of laboratory space and houses substantial HTS and HCS assay development and screening instrumentation capabilities. CLS has access to a broad spectrum of diverse and focused small-molecule collections, several integrated liquid handling systems, and a plethora of detection instruments, capable of performing assays in any mode, including live-cell image-based assays requiring temperature and CO2 control. The Prebys Center grew out of the Cancer Center's CLS Shared Resource, which was initiated in the 2003 CCSG renewal. This support has been leveraged with several large grant awards and philanthropic funds. Initially awarded a grant as one of ten NIH Molecular Libraries Screening Network Comprehensive Centers, the Prebys Center was later selected as one of four NIH- designated Molecular Libraries Probe Production Centers Network comprehensive screening centers. It is also one of seven dedicated Centers for the NCI Chemical Biology Consortium (CBC). Despite the growth of the Prebys Center, the CLS Core remains of crucial importance to Center investigators because it provides an important interactive entry point to ensure that they derive the maximum scientific benefit from these world class chemical biology and drug discovery capabilities, enabling both fundamental and translational scientific endeavors. In the past 5 years, the Core has additionally enabled >100 assay development projects for Cancer Center investigators, resulting in >25 full HTS campaigns to support the goal of early translation. It has provided services for 36 Center investigators representing all three programs. The data generated have supported 24 successful grants from 16 Center members and numerous publications, including 20 publications co-authored by CLS staff.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting the mutant promoter of Telomerase Reverse Transcriptase (TERT)
  • 批准号:
    10677899
  • 项目类别:
  • 资助金额:
    $77.22万
  • 财政年份:
    2023
  • 负责人:
    Michael Jackson
  • 依托单位:
Brain-penetrant GPR88 agonists as novel therapeutics for opioid abuse
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
Preventing Tau uptake by novel inhibitors of tau binding to LRP1
海外基金